FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Richard Hoetelmans

Research Profile

Chemicals & Drugs

Disorders

HIV Infections

Living Beings

HIV-1

Procedures

Physiology

Drug Interactions

Concepts & Ideas

Co-author Network

Publications

TOP 3
Thomas N Kakuda; Samantha Abel; John Davis; Julia Hamlin; Monika Schöller-Gyüre; Rebecca Mack; Noella Ndongo; Wendy Petit; Caroline Ridgway; Vanitha Sekar; Sarah Tweedy; Richard Hoetelmans
Pharmacokinetic interactions of maraviroc with darunavir-ritonavir, etravirine, and etravirine-darunavir-ritonavir in healthy volunteers: results of two drug interaction trials.
Vanitha Sekar; Frank Tomaka; Eric Lefebvre; Martine De Pauw; Tony Vangeneugden; Wim van den Brink; Richard Hoetelmans
Pharmacokinetic interactions between darunavir/ritonavir and opioid maintenance therapy using methadone or buprenorphine/naloxone.
Thomas N Kakuda; Monika Schöller-Gyüre; Richard Hoetelmans
Pharmacokinetic interactions between etravirine and non-antiretroviral drugs.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Richard Hoetelmans (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Thomas N Kakuda; Samantha Abel; John Davis; Julia Hamlin; Monika Schöller-Gyüre; Rebecca Mack; Noella Ndongo; Wendy Petit; Caroline Ridgway; Vanitha Sekar; Sarah Tweedy; Richard Hoetelmans
Pharmacokinetic interactions of maraviroc with darunavir-ritonavir, etravirine, and etravirine-darunavir-ritonavir in healthy volunteers: results of two drug interaction trials.
Antimicrobial agents and chemotherapy 2011;55(5):2290-6.
2011: Vanitha Sekar; Frank Tomaka; Eric Lefebvre; Martine De Pauw; Tony Vangeneugden; Wim van den Brink; Richard Hoetelmans
Pharmacokinetic interactions between darunavir/ritonavir and opioid maintenance therapy using methadone or buprenorphine/naloxone.
Journal of clinical pharmacology 2011;51(2):271-8.
2011: Thomas N Kakuda; Monika Schöller-Gyüre; Richard Hoetelmans
Pharmacokinetic interactions between etravirine and non-antiretroviral drugs.
Clinical pharmacokinetics 2011;50(1):25-39.
2010: T N Kakuda; J R Wade; E Snoeck; P Vis; M Schöller-Gyüre; M P Peeters; C Corbett; S Nijs; J Vingerhoets; L Leopold; G De Smedt; B J Woodfall; Richard Hoetelmans
Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients.
Clinical pharmacology and therapeutics 2010;88(5):695-703.
2010: Vanitha Sekar; Ludo Lavreys; Tom Van de Casteele; Cindy Berckmans; Sabrina Spinosa-Guzman; Tony Vangeneugden; Martine De Pauw; Richard Hoetelmans
Pharmacokinetics of darunavir/ritonavir and rifabutin coadministered in HIV-negative healthy volunteers.
Antimicrobial agents and chemotherapy 2010;54(10):4440-5.
2010: Vanitha Sekar; Sabrina Spinosa-Guzman; Els De Paepe; Tanja Stevens; Frank Tomaka; Martine De Pauw; Richard Hoetelmans
Pharmacokinetics of multiple-dose darunavir in combination with low-dose ritonavir in individuals with mild-to-moderate hepatic impairment.
Clinical pharmacokinetics 2010;49(5):343-50.
2010: Monika Schöller-Gyüre; Thomas N Kakuda; Goedele De Smedt; Brian Woodfall; Cindy Berckmans; Monika Peeters; Richard Hoetelmans
Effects of hepatic impairment on the steady-state pharmacokinetics of etravirine 200 mg BID: an open-label, multiple-dose, controlled Phase I study in adults.
Clinical therapeutics 2010;32(2):328-37.
2010: Thomas N Kakuda; Monika Schöller-Gyüre; Richard Hoetelmans
Clinical perspective on antiretroviral drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor etravirine.
Antiviral therapy 2010;15(6):817-29.
2010: Vanitha Sekar; Eric Lefebvre; Tine De Marez; Martine De Pauw; Els De Paepe; Tony Vangeneugden; Richard Hoetelmans
Pharmacokinetic interaction between indinavir and darunavir with low-dose ritonavir in healthy volunteers.
Intervirology 2010;53(3):176-82.
2009: Vanitha J Sekar; Eric Lefebvre; Kris Mariën; Martine De Pauw; Tony Vangeneugden; Anton Pozniak; Richard Hoetelmans
Pharmacokinetic interaction between nevirapine and darunavir with low-dose ritonavir in HIV-1-infected patients.
British journal of clinical pharmacology 2009;68(1):116-9.
2009: Monika Schöller-Gyüre; Thomas N Kakuda; Brian Woodfall; Fatima Aharchi; Monika Peeters; Kati Vandermeulen; Richard Hoetelmans
Effect of steady-state etravirine on the pharmacokinetics and pharmacodynamics of ethinylestradiol and norethindrone.
Contraception 2009;80(1):44-52.
2009: T N Kakuda; M Schöller-Gyüre; G De Smedt; G Beets; F Aharchi; M P Peeters; K Vandermeulen; B J Woodfall; Richard Hoetelmans
Assessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers.
HIV medicine 2009;10(3):173-81.
2009: Monika Schöller-Gyüre; Thomas N Kakuda; Araz Raoof; Goedele De Smedt; Richard Hoetelmans
Clinical pharmacokinetics and pharmacodynamics of etravirine.
Clinical pharmacokinetics 2009;48(9):561-74.
2008: Matt S Anderson; Thomas N Kakuda; William Hanley; Jutta Miller; James T Kost; Randall Stoltz; Larissa A Wenning; Julie A Stone; Richard Hoetelmans; John A Wagner; Marian Iwamoto
Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects.
Antimicrobial agents and chemotherapy 2008;52(12):4228-32.
2008: Monika Schöller-Gyüre; Marta Boffito; Anton L Pozniak; Ruud Leemans; Thomas N Kakuda; Brian Woodfall; Veerle Vyncke; Monika Peeters; Kati Vandermeulen; Richard Hoetelmans
Effects of different meal compositions and fasted state on the oral bioavailability of etravirine.
Pharmacotherapy 2008;28(10):1215-22.
2008: Monika Schöller-Gyüre; Thomas N Kakuda; Goedele De Smedt; Hilde Vanaken; Marie-Paule Bouche; Monika Peeters; Brian Woodfall; Richard Hoetelmans
A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-negative volunteers.
British journal of clinical pharmacology 2008;66(4):508-16.
2008: Vanitha J Sekar; Eric Lefebvre; Martine De Pauw; Tony Vangeneugden; Richard Hoetelmans
Pharmacokinetics of darunavir/ritonavir and ketoconazole following co-administration in HIV-healthy volunteers.
British journal of clinical pharmacology 2008;66(2):215-21.
2008: Monika Peeters; Katrien Janssen; Thomas N Kakuda; Monika Schöller-Gyüre; Ruth Lachaert; Richard Hoetelmans; Brian Woodfall; Goedele De Smedt
Etravirine has no effect on QT and corrected QT interval in HIV-negative volunteers.
The Annals of pharmacotherapy 2008;42(6):757-65.
2008: Monika Schöller-Gyüre; Wim van den Brink; Thomas N Kakuda; Brian Woodfall; Goedele de Smedt; Hilde Vanaken; Tanja Stevens; Monika Peeters; Kati Vandermeulen; Richard Hoetelmans
Pharmacokinetic and pharmacodynamic study of the concomitant administration of methadone and TMC125 in HIV-negative volunteers.
Journal of clinical pharmacology 2008;48(3):322-9.
2008: Thomas N Kakuda; Monika Schöller-Gyüre; Cassy Workman; Keikawus Arastéh; Anton L Pozniak; Goedele De Smedt; Greet Beets; Monika Peeters; Kati Vandermeulen; Brian J Woodfall; Richard Hoetelmans
Single- and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients.
Antiviral therapy 2008;13(5):655-61.
2008: Vanitha J Sekar; Eric Lefebvre; Sabrina Spinosa Guzman; Elise Felicione; Martine De Pauw; Tony Vangeneugden; Richard Hoetelmans
Pharmacokinetic interaction between ethinyl estradiol, norethindrone and darunavir with low-dose ritonavir in healthy women.
Antiviral therapy 2008;13(4):563-9.
2008: V Sekar; E Lefebvre; T De Marez; M De Pauw; E De Paepe; T Vangeneugden; Richard Hoetelmans
Effect of repeated doses of darunavir plus low-dose ritonavir on the pharmacokinetics of sildenafil in healthy male subjects: phase I randomized, open-label, two-way crossover study.
Clinical drug investigation 2008;28(8):479-85.
2008: David Back; Vanitha Sekar; Richard Hoetelmans
Darunavir: pharmacokinetics and drug interactions.
Antiviral therapy 2008;13(1):1-13.
2008: Vanitha J Sekar; Sabrina Spinosa-Guzman; Els De Paepe; Martine De Pauw; Tony Vangeneugden; Eric Lefebvre; Richard Hoetelmans
Darunavir/ritonavir pharmacokinetics following coadministration with clarithromycin in healthy volunteers.
Journal of clinical pharmacology 2008;48(1):60-5.
2007: Vanitha J Sekar; Eric Lefebvre; Kris Mariën; Martine De Pauw; Tony Vangeneugden; Richard Hoetelmans
Pharmacokinetic interaction between darunavir and saquinavir in HIV-negative volunteers.
Therapeutic drug monitoring 2007;29(6):795-801.
2007: Richard Hoetelmans; Kris Mariën; Martine De Pauw; Andrew Hill; Monika Peeters; Vanitha J Sekar; Piet De Doncker; Brian Woodfall; Eric Lefebvre
Pharmacokinetic interaction between TMC114/ritonavir and tenofovir disoproxil fumarate in healthy volunteers.
British journal of clinical pharmacology 2007;64(5):655-61.
2007: Marta Boffito; Alan Winston; Akil Jackson; Carl Fletcher; Anton Pozniak; Mark Nelson; Graeme Moyle; Izabela Tolowinska; Richard Hoetelmans; Diego Miralles; Brian Gazzard
Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance.
AIDS (London, England) 2007;21(11):1449-55.
2007: Vanitha J Sekar; Dries Kestens; Sabrina Spinosa-Guzman; Martine De Pauw; Els De Paepe; Tony Vangeneugden; Eric Lefebvre; Richard Hoetelmans
The effect of different meal types on the pharmacokinetics of darunavir (TMC114)/ritonavir in HIV-negative healthy volunteers.
Journal of clinical pharmacology 2007;47(4):479-84.
2007: Jeffrey P Nadler; Daniel S. Berger; Gary Blick; Paul J Cimoch; Calvin J Cohen; Richard N Greenberg; Charles B Hicks; Richard Hoetelmans; Kathy J Iveson; Dushyantha Jayaweera; Anthony M Mills; Monika P Peeters; Peter Ruane; Peter Shalit; Shannon R Schrader; Stephen M Smith; Corklin R Steinhart; Melanie Thompson; Johan Vingerhoets; Ellen Voorspoels; Douglas Ward; Brian Woodfall
Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis.
AIDS (London, England) 2007;21(6):F1-10.
2007: Vanitha J Sekar; Eric Lefebvre; Els De Paepe; Tine De Marez; Martine De Pauw; Wim Parys; Richard Hoetelmans
Pharmacokinetic interaction between darunavir boosted with ritonavir and omeprazole or ranitidine in human immunodeficiency virus-negative healthy volunteers.
Antimicrobial agents and chemotherapy 2007;51(3):958-61.
2007: Monika Schöller-Gyüre; Thomas N Kakuda; Vanitha J Sekar; Brian Woodfall; Goedele de Smedt; Eric Lefebvre; Monika Peeters; Richard Hoetelmans
Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers.
Antiviral therapy 2007;12(5):789-96.
2007: Vanitha J Sekar; Martine De Pauw; Kris Mariën; Monika Peeters; Eric Lefebvre; Richard Hoetelmans
Pharmacokinetic interaction between TMC114/r and efavirenz in healthy volunteers.
Antiviral therapy 2007;12(4):509-14.
2007: Vanitha J Sekar; Eric Lefebvre; Tine De Marez; Sabrina Spinosa-Guzman; Martine De Pauw; Els De Paepe; Tony Vangeneugden; Richard Hoetelmans
Pharmacokinetics of darunavir (TMC114) and atazanavir during coadministration in HIV-negative, healthy volunteers.
Drugs in R&D 2007;8(4):241-8.
2006: Frank-Detlef Goebel; Alexy Yakovlev; Anton L Pozniak; Elena Vinogradova; Griet Boogaerts; Richard Hoetelmans; Marie-Pierre de Bethune; Monika Peeters; Brian Woodfall
Short-term antiviral activity of TMC278--a novel NNRTI--in treatment-naive HIV-1-infected subjects.
AIDS (London, England) 2006;20(13):1721-6.
2005: Andrea Antinori; Carlo Federico Perno; Maria Letizia Giancola; Federica Forbici; Giuseppe Ippolito; Richard Hoetelmans; Stephen C Piscitelli
Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005;41(12):1787-93.
2005: Michael Sproat; Anton L Pozniak; Monika Peeters; Bart Winters; Richard Hoetelmans; Neil M Graham; Brian G Gazzard
The influence of the M184V mutation in HIV-1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosine.
Antiviral therapy 2005;10(2):357-61.
2004: David Burger; Alina S Bergshoeff; Ronald de Groot; Diana M Gibb; Sarah Walker; Jean-Marc Tréluyer; Richard Hoetelmans
Maintaining the nelfinavir trough concentration above 0.8 mg/L improves virologic response in HIV-1-infected children.
The Journal of pediatrics 2004;145(3):403-5.
2004: Antonella Castagna; Nicola Gianotti; Laura Galli; Anna Danise; Hamid Hasson; Enzo Boeri; Richard Hoetelmans; David Nauwelaers; Adriano Lazzarin
The NIQ of lopinavir is predictive of a 48-week virological response in highly treatment-experienced HIV-1-infected subjects treated with a lopinavir/ritonavir-containing regimen.
Antiviral therapy 2004;9(4):537-43.
2004: Andrea Antinori; Alessandro Cozzi-Lepri; Adriana Ammassari; Maria Paola Trotta; David Nauwelaers; Richard Hoetelmans; Rita Murri; Sara Melzi; Pasquale Narciso; Paola Nasta; Mauro Zaccarelli; Paola Santopadre; Jacopo Vecchiet; Crescenzo Maria Izzo; Antonella d'Arminio Maonforte
Relative prognostic value of self-reported adherence and plasma NNRTI/PI concentrations to predict virological rebound in patients initially responding to HAART.
Antiviral therapy 2004;9(2):291-6.
2004: Andrea De Luca; Francesco Baldini; Antonella Cingolani; Simona Di Giambenedetto; Richard Hoetelmans; Roberto Cauda
Deep salvage with amprenavir and lopinavir/ritonavir: correlation of pharmacokinetics and drug resistance with pharmacodynamics.
Journal of acquired immune deficiency syndromes (1999) 2004;35(4):359-66.
2003: Peter Cardiello; Tarika Samor; David Burger; Richard Hoetelmans; Apicha Mahanontharit; Kiat Ruxrungtham; Joep M A Lange; David A Cooper; Praphan Phanuphak
Pharmacokinetics of lower doses of saquinavir soft-gel caps (800 and 1200 mg twice daily) boosted with itraconazole in HIV-1-positive patients.
Antiviral therapy 2003;8(3):245-9.
2003: David Burger; Patricia W H Hugen; Rob E Aarnoutse; Richard Hoetelmans; Marielle Jambroes; Pythia T Nieuwkerk; Gerrit Schreij; M M E Schneider; Marchina E Van Der Ende; Joep M A Lange
Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations.
Therapeutic drug monitoring 2003;25(1):73-80.
2002: Rolf P G van Heeswijk; Henriëtte J Scherpbier; Linda A de Koning; Hugo S A Heymans; Joep M A Lange; Jos H Beijnen; Richard Hoetelmans
The pharmacokinetics of nelfinavir in HIV-1-infected children.
Therapeutic drug monitoring 2002;24(4):487-91.
2002: John D Baxter; Thomas C Merigan; Deborah N Wentworth; James D Neaton; Marie L Hoover; Richard Hoetelmans; Stephen C Piscitelli; Werner H A Verbiest; Douglas Mayers
Both baseline HIV-1 drug resistance and antiretroviral drug levels are associated with short-term virologic responses to salvage therapy.
AIDS (London, England) 2002;16(8):1131-8.
2002: Peter Cardiello; Rolf P G van Heeswijk; Elly A M Hassink; Preeyaporn Srasuebkul; Apicha Mahanontharit; Tarika Samor; Wassana Worarien; Jos H Beijnen; Richard Hoetelmans; Kiat Ruxrungtham; David A Cooper; Joep M A Lange; Praphan Phanuphak
Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study.
Journal of acquired immune deficiency syndromes (1999) 2002;29(5):464-70.
2002: Chokechai Rongkavilit; Rolf P G van Heeswijk; Sompop Limpongsanurak; Pimolrat Thaithumyanon; Chantana Boonrod; Elly A M Hassink; Aeumporn Srigritsanapol; Theshinee Chuenyam; Sasiwimol Ubolyam; Richard Hoetelmans; Kiat Ruxrungtham; Joep M A Lange; David A Cooper; Praphan Phanuphak
Dose-escalating study of the safety and pharmacokinetics of nelfinavir in HIV-exposed neonates.
Journal of acquired immune deficiency syndromes (1999) 2002;29(5):455-63.
2002: David Back; Giorgio Gatti; Carl Fletcher; Rodolphe Garaffo; Richard Haubrich; Richard Hoetelmans; Michael Kurowski; Andrew Luber; Concepta Merry; Carlo Federico Perno
Therapeutic drug monitoring in HIV infection: current status and future directions.
AIDS (London, England) 2002;16 Suppl 1():S5-37.
2002: Monique M R de Maat; Suzanne V Frankfort; Ron A A Mathôt; Jan W Mulder; Pieter L Meenhorst; Eric C M van Gorp; Cornelis H W Koks; Richard Hoetelmans; Anthonius de Boer; Jos H Beijnen
Discrepancies between medical and pharmacy records for patients on anti-HIV drugs.
The Annals of pharmacotherapy 2002;36(3):410-5.
2002: Rieneke van Praag; Elisabeth C M van Weert; Rolf P G van Heeswijk; Xiao-Jian Zhou; Jean-Pierre Sommadossi; Suzanne Jurriaans; Joep M A Lange; Richard Hoetelmans; Jan M Prins
Stable concentrations of zidovudine, stavudine, lamivudine, abacavir, and nevirapine in serum and cerebrospinal fluid during 2 years of therapy.
Antimicrobial agents and chemotherapy 2002;46(3):896-9.
2002: Rolf P G van Heeswijk; James W T Cohen Stuart; David Burger; Jos H Beijnen; Jan C C Borleffs; Richard Hoetelmans
Long-term suppression of viral replication despite low plasma saquinavir concentrations in the CHEESE Study.
British journal of clinical pharmacology 2002;53(2):211-2.
2001: Rolf P G van Heeswijk; Agnes I Veldkamp; Jan W Mulder; Pieter L Meenhorst; Joep M A Lange; Jos H Beijnen; Richard Hoetelmans
Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience.
Antiviral therapy 2001;6(4):201-29.
2001: Agnes I Veldkamp; Rolf P G van Heeswijk; Jan W Mulder; Pieter L Meenhorst; Richard Hoetelmans; Joep M A Lange; Jos H Beijnen
Limited sampling strategies for the estimation of the systemic exposure to the HIV-1 nonnucleoside reverse transcriptase inhibitor nevirapine.
Therapeutic drug monitoring 2001;23(6):606-11.
2001: Chokechai Rongkavilit; Pimolrat Thaithumyanon; Theshinee Chuenyam; B D Damle; Sompop Limpongsanurak; C Boonrod; A Srigritsanapol; Elly A M Hassink; Richard Hoetelmans; David A Cooper; Joep M A Lange; Kiat Ruxrungtham; Praphan Phanuphak
Pharmacokinetics of stavudine and didanosine coadministered with nelfinavir in human immunodeficiency virus-exposed neonates.
Antimicrobial agents and chemotherapy 2001;45(12):3585-90.
2001: Rieneke van Praag; Rolf P G van Heeswijk; Suzanne Jurriaans; Joep M A Lange; Richard Hoetelmans; Jan M Prins
Penetration of the nucleoside analogue abacavir into the genital tract of men infected with human immunodeficiency virus type 1.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2001;33(8):e91-2.
2001: Rieneke van Praag; Sjoerd Repping; Jan W A de Vries; Joep M A Lange; Richard Hoetelmans; Jan M Prins
Pharmacokinetic profiles of nevirapine and indinavir in various fractions of seminal plasma.
Antimicrobial agents and chemotherapy 2001;45(10):2902-7.
2001: Pythia T Nieuwkerk; Mirjam A G Sprangers; David Burger; Richard Hoetelmans; Patricia W H Hugen; Sven A Danner; Marchina E Van Der Ende; M M E Schneider; G Schrey; Pieter L Meenhorst; Herman Sprenger; Robbert H Kauffmann; Marielle Jambroes; Margaret A Chesney; Frank de Wolf; Joep M A Lange
Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study.
Archives of internal medicine 2001;161(16):1962-8.
2001: Richard Hoetelmans; V Miller
Therapeutic drug monitoring in HIV disease.
Journal of HIV therapy 2001;6(3):65-7.
2001: Cornelis H W Koks; Kristel M L Crommentuyn; Richard Hoetelmans; Ron A A Mathôt; Jos H Beijnen
Can fluconazole concentrations in saliva be used for therapeutic drug monitoring?
Therapeutic drug monitoring 2001;23(4):449-53.
2001: Agnes I Veldkamp; Rolf P G van Heeswijk; Jan W Mulder; Pieter L Meenhorst; Gerrit Schreij; Siebe van der Geest; Joep M A Lange; Jos H Beijnen; Richard Hoetelmans
Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals.
Journal of acquired immune deficiency syndromes (1999) 2001;27(4):344-9.
2001: Agnes I Veldkamp; M Harris; J S Montaner; G Moyle; B Gazzard; M Youle; M Johnson; MO Kwakkelstein; Hilde Carlier; Remko van Leeuwen; Jos H Beijnen; Joep M A Lange; Peter Reiss; Richard Hoetelmans
The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons.
The Journal of infectious diseases 2001;184(1):37-42.
2001: Agnes I Veldkamp; Gerrit Jan Weverling; Joep M A Lange; J S Montaner; Peter Reiss; D A Cooper; STEFANO VELLA; D Hall; Jos H Beijnen; Richard Hoetelmans
High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals.
AIDS (London, England) 2001;15(9):1089-95.
2001: Cornelis H W Koks; Kristel M L Crommentuyn; Richard Hoetelmans; David Burger; P P Koopmans; Ron A A Mathôt; Jan W Mulder; Pieter L Meenhorst; Jos H Beijnen
The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals.
British journal of clinical pharmacology 2001;51(6):631-5.
2001: Rolf P G van Heeswijk; Agnes I Veldkamp; Jan W Mulder; Pieter L Meenhorst; J H Beijnen; Joep M A Lange; Richard Hoetelmans
Saliva as an alternative body fluid for therapeutic drug monitoring of the nonnucleoside reverse transcription inhibitor nevirapine.
Therapeutic drug monitoring 2001;23(3):255-8.
2001: Maarten Huisman; Johan W Smit; Hugh R Wiltshire; Richard Hoetelmans; Jos H Beijnen; Alfred H Schinkel
P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir.
Molecular pharmacology 2001;59(4):806-13.
2001: NA Foudraine; Suzanne Jurriaans; Gerrit Jan Weverling; David Burger; Richard Hoetelmans; Marijke Th L Roos; JJ Maas; Frank Miedema; Peter Reiss; Peter Portegies; Frank de Wolf; Joep M A Lange
Durable HIV-1 suppression with indinavir after failing lamivudine-containing double nucleoside therapy: a randomized controlled trial.
Antiviral therapy 2001;6(1):55-62.
2001: David Burger; Annemarie M C van Rossum; Patricia W H Hugen; MH Suur; Nico G Hartwig; S P M Geelen; Henriëtte J Scherpbier; Richard Hoetelmans; Arnold G Vulto; Ronald de Groot
Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children.
Antimicrobial agents and chemotherapy 2001;45(3):701-5.
2001: Monique M R de Maat; Richard Hoetelmans; R A Math t; Eric C M van Gorp; Pieter L Meenhorst; Jan W Mulder; Jos H Beijnen
Drug interaction between St John's wort and nevirapine.
AIDS (London, England) 2001;15(3):420-1.
2001: Rolf W Sparidans; Richard Hoetelmans; Jos H Beijnen
Liquid chromatographic assay for simultaneous determination of abacavir and mycophenolic acid in human plasma using dual spectrophotometric detection.
Journal of chromatography. B, Biomedical sciences and applications 2001;750(1):155-61.
2001: MH Reijers; Gerrit Jan Weverling; Suzanne Jurriaans; Marijke Th L Roos; Ferdinand W N M Wit; Hugo M Weigel; Reinier W Ten Kate; Jan W Mulder; Clemens Richter; Hadewych J M ter Hofstede; Herman Sprenger; Richard Hoetelmans; Hanneke Schuitemaker; Joep M A Lange
The ADAM study continued: maintenance therapy after 50 weeks of induction therapy.
AIDS (London, England) 2001;15(1):129-31.
2001: Richard Hoetelmans
Pharmacological exposure and the development of drug resistance in HIV.
Antiviral therapy 2001;6 Suppl 2():37-47.
2000: Emile F Schippers; Patricia W H Hugen; Jan den Hartigh; David Burger; Richard Hoetelmans; Leo G Visser; Frank P Kroon
No drug-drug interaction between nelfinavir or indinavir and mefloquine in HIV-1-infected patients.
AIDS (London, England) 2000;14(17):2794-5.
2000: Pablo Barreiro; Vincent Soriano; E Casas; Vicente Estrada; Maria Jesus Téllez; Richard Hoetelmans; Daniel González De Requena; I Jimenéz-Nácher; Juan González-Lahoz
Prevention of nevirapine-associated exanthema using slow dose escalation and/or corticosteroids.
AIDS (London, England) 2000;14(14):2153-7.
2000: Stephen Taylor; Rolf P G van Heeswijk; Richard Hoetelmans; Judith Workman; Susan M Drake; David J White; Deenan Pillay
Concentrations of nevirapine, lamivudine and stavudine in semen of HIV-1-infected men.
AIDS (London, England) 2000;14(13):1979-84.
2000: Rolf P G van Heeswijk; Agnes I Veldkamp; Jan W Mulder; Pieter L Meenhorst; Ferdinand W N M Wit; Peter Reiss; Joep M A Lange; MO Kwakkelstein; Jos H Beijnen; Richard Hoetelmans
Nevirapine plus didanosine: once or twice daily combination?
Journal of acquired immune deficiency syndromes (1999) 2000;25(1):93-5.
2000: Patricia W H Hugen; David Burger; M de Graaff; Hadewych J M ter Hofstede; Richard Hoetelmans; Kees Brinkman; Pieter L Meenhorst; Jan W Mulder; Peter P Koopmans; Yechiel A Hekster
Saliva as a specimen for monitoring compliance but not for predicting plasma concentrations in patients with HIV treated with indinavir.
Therapeutic drug monitoring 2000;22(4):437-45.
2000: EH Gisolf; Roelien H Enting; Suzanne Jurriaans; Frank de Wolf; Marchina E Van Der Ende; Richard Hoetelmans; Peter Portegies; Sven A Danner
Cerebrospinal fluid HIV-1 RNA during treatment with ritonavir/saquinavir or ritonavir/saquinavir/stavudine.
AIDS (London, England) 2000;14(11):1583-9.
2000: Rieneke van Praag; Gerrit Jan Weverling; Peter Portegies; Suzanne Jurriaans; X J Zhou; M L Turner-Foisy; Jean-Pierre Sommadossi; David Burger; Joep M A Lange; Richard Hoetelmans; Jan M Prins
Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir.
AIDS (London, England) 2000;14(9):1187-94.
2000: Rolf P G van Heeswijk; Agnes I Veldkamp; Jan W Mulder; Pieter L Meenhorst; Joep M A Lange; Jos H Beijnen; Richard Hoetelmans
Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot study.
AIDS (London, England) 2000;14(9):F103-10.
2000: Rolf W Sparidans; Richard Hoetelmans; Jos H Beijnen
Sensitive liquid chromatographic assay for amprenavir, a human immunodeficiency virus protease inhibitor, in human plasma, cerebrospinal fluid and semen.
Journal of chromatography. B, Biomedical sciences and applications 2000;742(1):185-92.
2000: Rolf P G van Heeswijk; Agnes I Veldkamp; Jan W Mulder; Pieter L Meenhorst; Ferdinand W N M Wit; Joep M A Lange; Sven A Danner; NA Foudraine; MO Kwakkelstein; Peter Reiss; Jos H Beijnen; Richard Hoetelmans
The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals.
AIDS (London, England) 2000;14(8):F77-82.
2000: EH Gisolf; Rolf P G van Heeswijk; Richard Hoetelmans; Sven A Danner
Decreased exposure to saquinavir in HIV-1-infected patients after long-term antiretroviral therapy including ritonavir and saquinavir.
AIDS (London, England) 2000;14(7):801-5.
2000: Cornelis H W Koks; Rolf P G van Heeswijk; Agnes I Veldkamp; Pieter L Meenhorst; Jan W Mulder; J T van der Meer; J H Beijnen; Richard Hoetelmans
Itraconazole as an alternative for ritonavir liquid formulation when combined with saquinavir.
AIDS (London, England) 2000;14(1):89-90.
2000: MH Reijers; Hugo M Weigel; A A Hart; Reinier W Ten Kate; Jan W Mulder; Peter Reiss; Hanneke Schuitemaker; Richard Hoetelmans; Gerrit Jan Weverling; Joep M A Lange
Toxicity and drug exposure in a quadruple drug regimen in HIV-1 infected patients participating in the ADAM study.
AIDS (London, England) 2000;14(1):59-67.
1999: Agnes I Veldkamp; Rolf W Sparidans; Richard Hoetelmans; Jos H Beijnen
Quantitative determination of abacavir (1592U89), a novel nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection.
Journal of chromatography. B, Biomedical sciences and applications 1999;736(1-2):123-8.
1999: Rolf W Sparidans; Agnes I Veldkamp; Richard Hoetelmans; Jos H Beijnen
Improved and simplified liquid chromatographic assay for adefovir, a novel antiviral drug, in human plasma using derivatization with chloroacetaldehyde.
Journal of chromatography. B, Biomedical sciences and applications 1999;736(1-2):115-21.
1999: Richard Hoetelmans
Antiretroviral drug level monitoring: the next routine test in HIV management?
Current opinion in infectious diseases 1999;12(6):593-5.
1999: Agnes I Veldkamp; Richard Hoetelmans; Jos H Beijnen; Jan W Mulder; Pieter L Meenhorst
Ritonavir enables combined therapy with rifampin and saquinavir.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1999;29(6):1586.
1999: Agnes I Veldkamp; Rolf P G van Heeswijk; Pieter L Meenhorst; Jan W Mulder; Joep M A Lange; Jos H Beijnen; Richard Hoetelmans
Quantitative determination of efavirenz (DMP 266), a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection.
Journal of chromatography. B, Biomedical sciences and applications 1999;734(1):55-61.
1999: Rolf P G van Heeswijk; Agnes I Veldkamp; Richard Hoetelmans; Jan W Mulder; Gerrit Schreij; A Hsu; Joep M A Lange; Jos H Beijnen; Pieter L Meenhorst
The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals.
AIDS (London, England) 1999;13(14):F95-9.
1999: Gerd Fätkenheuer; Richard Hoetelmans; N Hunn; Achim Schwenk; Caspar Franzen; M Reiser; Alexander Jütte; Jürgen Rockstroh; Volker Diehl; Bernd Salzberger
Salvage therapy with regimens containing ritonavir and saquinavir in extensively pretreated HIV-infected patients.
AIDS (London, England) 1999;13(12):1485-9.
1999: James W T Cohen Stuart; Rob Schuurman; David Burger; Peter P Koopmans; Herman Sprenger; Job R Juttmann; Clemens Richter; Pieter L Meenhorst; Richard Hoetelmans; Frank P Kroon; B Bravenboer; Dörte Hamann; Charles A B Boucher; Jan C C Borleffs
Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study).
AIDS (London, England) 1999;13(7):F53-8.
1999: Agnes I Veldkamp; Rolf P G van Heeswijk; Richard Hoetelmans; Pieter L Meenhorst; Jan W Mulder; Joep M A Lange; Jos H Beijnen
Rapid quantification of delavirdine, a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with fluorescence detection.
Journal of chromatography. B, Biomedical sciences and applications 1999;727(1-2):151-7.
1999: M Reiser; B Salzberger; A Stiepel; Richard Hoetelmans; Volker Diehl; G Fätkenheuer
Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy.
European journal of medical research 1999;4(2):54-8.
1999: Richard Hoetelmans
Pharmacological resistance to antiretroviral drugs.
Antiviral therapy 1999;4 Suppl 3():75-8.
1999: Richard Hoetelmans
Pharmacology of antiretroviral drugs.
Antiviral therapy 1999;4 Suppl 3():29-41.
1999: VR Nannan Panday; Richard Hoetelmans; Rolf P G van Heeswijk; Pieter L Meenhorst; M Inghels; Jan W Mulder; Jos H Beijnen
Paclitaxel in the treatment of human immunodeficiency virus 1-associated Kaposi's sarcoma--drug-drug interactions with protease inhibitors and a nonnucleoside reverse transcriptase inhibitor: a case report study.
Cancer chemotherapy and pharmacology 1999;43(6):516-9.
1998: Richard Hoetelmans; Rolf P G van Heeswijk; M Profijt; Jan W Mulder; Pieter L Meenhorst; Joep M A Lange; Peter Reiss; Jos H Beijnen
Comparison of the plasma pharmacokinetics and renal clearance of didanosine during once and twice daily dosing in HIV-1 infected individuals.
AIDS (London, England) 1998;12(17):F211-6.
1998: Richard Hoetelmans; M Profijt; Pieter L Meenhorst; Jan W Mulder; Rolf P G van Heeswijk; Jos H Beijnen
Co-trimoxazole and stavudine interference in a high-performance liquid chromatographic analysis for didanosine in human plasma.
Therapeutic drug monitoring 1998;20(6):669-72.
1998: Rolf P G van Heeswijk; Richard Hoetelmans; Remko Harms; Pieter L Meenhorst; Jan W Mulder; Joep M A Lange; Jos H Beijnen
Simultaneous quantitative determination of the HIV protease inhibitors amprenavir, indinavir, nelfinavir, ritonavir and saquinavir in human plasma by ion-pair high-performance liquid chromatography with ultraviolet detection.
Journal of chromatography. B, Biomedical sciences and applications 1998;719(1-2):159-68.
1998: Roelien H Enting; Richard Hoetelmans; Joep M A Lange; David Burger; J H Beijnen; Peter Portegies
Antiretroviral drugs and the central nervous system.
AIDS (London, England) 1998;12(15):1941-55.
1998: Rolf P G van Heeswijk; Richard Hoetelmans; Pieter L Meenhorst; Jan W Mulder; Jos H Beijnen
Rapid determination of nevirapine in human plasma by ion-pair reversed-phase high-performance liquid chromatography with ultraviolet detection.
Journal of chromatography. B, Biomedical sciences and applications 1998;713(2):395-9.
1998: Richard Hoetelmans; M Profijt; P L Mennhorst; Jan W Mulder; Jos H Beijnen
Quantitative determination of (-)-2'-deoxy-3'-thiacytidine (lamivudine) in human plasma, saliva and cerebrospinal fluid by high-performance liquid chromatography with ultraviolet detection.
Journal of chromatography. B, Biomedical sciences and applications 1998;713(2):387-94.
1998: Gerrit Jan Weverling; Joep M A Lange; Suzanne Jurriaans; Jan M Prins; Vladimir V Lukashov; Daan W Notermans; M Roos; Hanneke Schuitemaker; Richard Hoetelmans; Sven A Danner; Jaap Goudsmit; Frank de Wolf
Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy.
AIDS (London, England) 1998;12(11):F117-22.
1998: Richard Hoetelmans; MH Reijers; Gerrit Jan Weverling; Reinier W Ten Kate; Ferdinand W N M Wit; Jan W Mulder; Hugo M Weigel; P H J Frissen; M Roos; Suzanne Jurriaans; Hanneke Schuitemaker; Frank de Wolf; Jos H Beijnen; Joep M A Lange
The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy.
AIDS (London, England) 1998;12(11):F111-5.
1998: NA Foudraine; Richard Hoetelmans; Joep M A Lange; Frank de Wolf; Birgit H B van Benthem; JJ Maas; IP Keet; Peter Portegies
Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine.
Lancet 1998;351(9115):1547-51.
1998: Richard Hoetelmans; M van Essenberg; M Profijt; Pieter L Meenhorst; Jan W Mulder; Jos H Beijnen
High-performance liquid chromatographic determination of ritonavir in human plasma, cerebrospinal fluid and saliva.
Journal of chromatography. B, Biomedical sciences and applications 1998;705(1):119-26.
1998: Richard Hoetelmans
Sanctuary sites in HIV-1 infection.
Antiviral therapy 1998;3 Suppl 4():13-7.
1998: David Burger; Richard Hoetelmans; Patricia W H Hugen; Jan W Mulder; Pieter L Meenhorst; Peter P Koopmans; Kees Brinkman; M Keuter; Wil M V Dolmans; Yechiel A Hekster
Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy.
Antiviral therapy 1998;3(4):215-20.
1997: Richard Hoetelmans; M van Essenberg; Pieter L Meenhorst; Jan W Mulder; J H Beijnen
Determination of saquinavir in human plasma, saliva, and cerebrospinal fluid by ion-pair high-performance liquid chromatography with ultraviolet detection.
Journal of chromatography. B, Biomedical sciences and applications 1997;698(1-2):235-41.
1997: Richard Hoetelmans; Pieter L Meenhorst; Jan W Mulder; David Burger; Cornelis H W Koks; Jos H Beijnen
Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir.
Pharmacy world & science : PWS 1997;19(4):159-75.
1997: David Burger; Richard Hoetelmans; Peter P Koopmans; Pieter L Meenhorst; Jan W Mulder; Yechiel A Hekster; J H Beijnen
Clinically relevant drug interactions with antiretroviral agents.
Antiviral therapy 1997;2(3):149-65.
1997: Richard Hoetelmans; C L Kraaijeveld; Pieter L Meenhorst; Jan W Mulder; David Burger; Cornelis H W Koks; J H Beijnen
Penetration of 3'-amino-3'-deoxythymidine, a cytotoxic metabolite of zidovudine, into the cerebrospinal fluid of HIV-1-infected patients.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1997;15(2):131-6.
1997: David Burger; C A Boucher; Pieter L Meenhorst; C L Kraayeveld; Peter Portegies; Jan W Mulder; Richard Hoetelmans; J H Beijnen
HIV-1 RNA levels in the cerebrospinal fluid may increase owing to damage to the blood-brain barrier.
Antiviral therapy 1997;2(2):113-7.
1996: Richard Hoetelmans; J M Otten; Cornelis H W Koks; M Soesan; J H Beijnen
Combined dapsone and clofazimine intoxication.
Human & experimental toxicology 1996;15(8):625-8.
1996: Richard Hoetelmans; David Burger; Pieter L Meenhorst; Jos H Beijnen
Pharmacokinetic individualisation of zidovudine therapy. Current state of pharmacokinetic-pharmacodynamic relationships.
Clinical pharmacokinetics 1996;30(4):314-27.
1996: Richard Hoetelmans; Jan Schornagel; Wim W ten Bokkel Huinink; Jos H Beijnen
Hypersensitivity reactions to etoposide.
The Annals of pharmacotherapy 1996;30(4):367-71.
1995: David Burger; C L Kraayeveld; Pieter L Meenhorst; Jan W Mulder; Richard Hoetelmans; Cornelis H W Koks; Jos H Beijnen
Study on didanosine concentrations in cerebrospinal fluid. Implications for the treatment and prevention of AIDS dementia complex.
Pharmacy world & science : PWS 1995;17(6):218-21.
1994: H A Rongen; Richard Hoetelmans; Auke Bult; Wouter P van Bennekom
Chemiluminescence and immunoassays.
Journal of pharmaceutical and biomedical analysis 1994;12(4):433-62.